Clinical Need

Traditional inflammation tests like CRP are often insensitive and cannot distinguish whether tissue is actively being damaged, repaired, or both simultaneously. Even when biomarkers such as LCN2 or LCN2-MMP9 are measured, they are usually reported as simple concentration values with little context, leaving their relationship to disease activity or treatment effect unclear.

Interpretation is often left to individual clinicians, who may use different “rules of thumb” and thresholds when looking at these markers. In diseases like Axial Spondyloarthritis, many people with active disease can have marker values that look similar to those of “Healthy” individuals, so there is no clear line that reliably separates health from chronic disease just by looking at one biomarker.

KeyIn-1 goes beyond this by using LCN2 and LCN2–MMP9, combined with AI-driven analytics, to detect earlier molecular shifts and interpret them as patterns of inflammation intensity, repair activity, and their balance over time, revealing hidden inflammation and treatment effects that traditional blood tests often miss.

KeyIn-1 combines LCN2 and LCN2–MMP9 with AI-driven analytics to reveal hidden inflammatory signals. By making inflammation and repair measurable and actionable, it supports more confident diagnosis and enables objective tracking of inflammation intensity, repair activity, their balance over time, and treatment effects that are often missed by subjective clinical assessment and conventional blood tests.